Good news! Fecal transplants keep on giving!
"Three trials provide compelling evidence that faecal microbiota transplantation (FMT) can boost the effectiveness of immunotherapy in advanced solid tumors ... in an analysis of three studies ... But challenges for safety, donor selection and product development remain.
Tumours partially or completely shrunk in 75% of FMT-treated people who underwent immunotherapy with melanoma, 80% of those with non-small cell lung cancer and 50% with metastatic renal cell carcinoma (RCC) across the studies. The only randomized, placebo-controlled trial, which evaluated immunotherapy plus an oral drug with or without FMT in individuals with metastatic RCC, did not find statistically significant 12-month progression-free survival. But it did find that FMT increased the proportion of people whose tumours shrunk (52% versus 32%)."
Microbiome modulation in cancer immunotherapy (no public access) "Three landmark trials confirm that fecal microbiota transplantation is a promising approach to enhancing immunotherapy efficacy in advanced solid tumors. The trials also provide insights with major implications for microbiome therapeutic development."
Three studies suggest that FMT improves immunotherapy responsiveness not only by bolstering the growth of good bacteria, which improves the microbiome to help the immune system respond to cancer, but also by killing off bad bacteria.
No comments:
Post a Comment